Managing Elevated LDL-C: New Guidelines and New Agents
Elevated low-density lipoprotein cholesterol (LDL-C) levels are a major contributor to arteriosclerotic cardiovascular disease (ASCVD). In 2018, the AHA and ACC jointly published an updated guideline on blood cholesterol management, providing new guidance on primary and secondary ASCVD prevention including LDL-C threshold levels for treatment and outlining the role of more recently approved agents. In addition, the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) published guidelines in 2019 that recommended lower LDL-C goal levels, a new definition of high-risk patients that expanded the number of patients in this group, and recommends more aggressive use of non-statin agents compared to the 2018 ACC/AHA guidelines.
Unfortunately, mean LDL-C levels in the US continue to rise. To achieve the AHA’s 2030 impact goal, the new guidelines and new agents will need to be incorporated into clinical practice. This educational activity, “Managing Elevated LDL-C: New Guidelines and New Agents” will provide cardiologists with information about the new guidelines, expert opinion on the role of agents recently approved by the FDA after the guideline publication, and a review of results from trials of agents in late stage development.
This activity is intended for cardiologists and other health care professionals who manage patients with dyslipidemia.
At the conclusion of this activity, participants should be able to:
- Provide individualized primary prevention plans for patients with elevated LDL-C levels using the 2018 cholesterol guidelines
- Develop individualized secondary prevention strategies for patients with elevated LDL-C levels based on recommendations in the 2018 cholesterol guidelines
- Employ adjunctive non-statin agents to intensify LDL-C management when statins alone do not achieve 2018 blood cholesterol guideline goals
- Evaluate the most current efficacy and safety data for non-statin agents approved for managing elevated LDL-C
This program is supported by an educational grant from Amgen and Novartis Pharmaceuticals Corporation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.